Mercurio, I must admit this IS a viable solution for Janet Woodcock in her handling of Cytodyn's Leronlimab aka Vyrologix. You've identified a path where she can deflect critcism, while appeasing her "future employers, by not allwoing full approval. This clever positioning will allow her to stay on course for a cushy position with Big pharma, when she leaves the FDA.
Market Data 
Markets 
AI
